Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
 

 

Sponsors and Collaborators


Continue Reading

 

Contact
NCI Referral Office
1-888-NCI-1937
 
ClinicalTrials.gov Identifier
NCT01092182